Capivasertib

SKU: orb1307109

Description

Capivasertib (AZD5363) is an orally active, pan-AKT inhibitor targeting Akt1, Akt2, and Akt3 with low nanomolar potency. It demonstrates antitumor efficacy in preclinical models of breast cancer and is widely used in research exploring AKT signaling in oncology, supported by both in vitro and in vivo studies.

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 1143532-39-1
• MW: 428.92
• Purity: 97.59% (May vary between batches)
• Formula: C₂₁H₂₅ClN₆O₂
• SMILES: NC1(CCN(CC1)c1ncnc2[nH]ccc12)C(=O)N[C@@H](CCO)c1ccc(Cl)cc1
• Target: Autophagy,PKA,Akt,mTOR
• Solubility: DMSO:130 mg/mL (303.09 mM);Ethanol:1 mg/mL (2.33 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:8 mg/mL (18.65 mM);H2O:Insoluble

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Inhibitor, inhibit, mTOR (p70S6K), Akt, AZD 5363, Autophagy, AZD5363, AZD-5363, Akt1, Akt2, Akt3, Capivasertib, Protein kinase B, PKB, PKA

Quick Database Links

Gene Symbol

Autophagy,PKA,Akt,mTOR

Petros A Tyrakis 1, Domen Kampjut 1, Georgina F Steele 1, H Jonathan G Lindström 1, Deborah Chirnomas 1, Benjamin D Hopkins 2, Marcus D Goncalves 3, Siddhartha Mukherjee 4, Lewis C Cantley 5, Oliver D K Maddocks 6 Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kα potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models Br J Cancer ., (2025)

PubMed: 40360883